The Sulfasalazine Market is estimated to be valued at US$ 2.01 Bn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The Sulfasalazine Market is growing at a significant pace due to the rising incidences of inflammatory bowel disease and arthritis worldwide. Sulfasalazine has been commonly used in the treatment of arthritis and inflammatory bowel disease since 1950. It is used to treat both rheumatoid arthritis and ulcerative colitis. The availability of generic variants and therapeutic efficacy of sulfasalazine is driving the market growth.
Market Overview:
Sulfasalazine is an anti-inflammatory drug majorly used for the treatment of rheumatoid arthritis and ulcerative colitis. It works by blocking the inflammation causing chemicals in the body. Sulfasalazine comes in tablet form and is prescribed for oral administration along with corticosteroids and anti-TNF drugs for effective management of arthritis and bowel inflammation.
Market key trends:
The Sulfasalazine Market Size is witnessing high growth owing to rising incidences of inflammatory bowel disease. According to the Crohn's & Colitis Foundation, inflammatory bowel disease (IBD) affects over 3 million Americans. IBD encompasses chronic diseases including Crohn's disease and ulcerative colitis. Sulfasalazine acts as a first line of defense in the treatment of mild to moderate IBD cases. It works by reducing intestinal inflammation. Increasing awareness about early diagnosis and treatment of IBD is creating significant demand for sulfasalazine drugs. Additionally, introduction of new drug delivery formulations of sulfasalazine such as matrix controlled-release tablets are also supporting the market growth.
Porter’s Analysis
Threat of new entrants: Low capital requirements along with availability of generic drugs makes entry easy in the sulfasalazine market. However, the presence of stringent regulations poses a threat to new entrants.
Bargaining power of buyers: Large buyers have significant bargaining power due to availability of generic alternatives. This bargaining power reduces selling prices.
Bargaining power of suppliers: Few pharmaceutical suppliers or manufacturers of active pharmaceutical ingredients have a significant influence over prices due to supply constraints.
Threat of new substitutes: Newer targeted therapies have reduced the usage of sulfasalazine drugs for conditions like rheumatoid arthritis. However, substitutes have limitations which retain the scope for sulfasalazine.
Competitive rivalry: The sulfasalazine market witnesses intense competition due to presence of generic drugs.
SWOT Analysis
Strength: High efficacy and safety of sulfasalazine drugs for conditions like ulcerative colitis and rheumatoid arthritis. Growing aging population increases patient pool.
Weakness: Availability of costly newer biologics and targeted therapies. Possible side effects like gastrointestinal problems limit patient acceptance.
Opportunity: Rising healthcare spending in emerging markets boosts overall sales. Increasing disease burden of autoimmune and inflammatory disorders widens the consumer base.
Threats: Fierce competition from low-cost generic drugs. Stringent regulations and compliance requirements hike overall costs.
Key Takeaways
The global sulfasalazine market is expected to witness high growth, exhibiting CAGR of 5.7% over the forecast period, due to increasing disease burden of rheumatoid arthritis, ulcerative colitis and other chronic inflammatory disorders. North America is expected to continue its dominance in the global sulfasalazine market over the forecast period. This is attributed to robust healthcare systems, existence of top players and presence of target population. Asia Pacific is likely to exhibit the fastest growth owing to increasing healthcare spending, large patient population and rising medical tourism.
Regional analysis
Asia Pacific region is projected to witness the fastest growth in the sulfasalazine market, primarily driven by China and India. Improving access to healthcare systems and increasing disposable income enhance the region's potential. Growing medical tourism supports market revenues.
Key players
Key players operating in the sulfasalazine market are Pfizer Inc., Teva Pharmaceuticals, Mylan N.V., Dr. Reddy's Laboratories, Zydus Cadila, Sun Pharmaceutical Industries, Aspen Pharmacare, Apotex Inc., Sandoz (a division of Novartis), Lupin Limited.
Read Our More Blogs : https://www.dailyprbulletin.com/sulfasalazine-market-forecast-outlook-trend-2023-2030/
